Fungal Diagnostics RealSeq's cfRNA fragmentomics platform targets fungal pathogens such as Valley Fever, presenting a sales opportunity with infectious disease labs and hospitals in California and other endemic regions. Position the platform as a liquid biopsy solution that enables rapid, noninvasive diagnosis and disease management, with a focus on labs seeking next gen diagnostics for rising fungal threats.

Partnership Potential With proprietary bias-free small RNA/miRNA library construction and cf-RNA analysis, RealSeq can pursue licensing, co development, or OEM partnerships with larger diagnostics players and CROs to accelerate market access, scale production, and expand distribution beyond its current footprint.

Validation Roadmap The 300K NHGRI grant underscores credibility and a path for clinical validation. Opportunities exist to run multi site validation studies with academic medical centers and to build evidence to support regulatory filings and payer reimbursement discussions.

Workflow Fit The platform is designed for integration with standard NGS workflows and LIMS, enabling easy adoption by sequencing cores and clinical labs. Target pilots in high volume labs and hospital systems to demonstrate workflow compatibility, data interoperability, and actionable reporting.

Growth Signals Current revenue range and a lean team suggest scalable growth through direct lab sales, strategic partnerships, and channel distribution. Leverage grant momentum and early customer wins to build credibility with larger enterprise customers and accelerate multi site deployments.